Objectives: RBx 11760, a novel oxazolidinone, was investigated for in vitro and in vivo activity against Clostridium difficile.
Introduction
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacillus, and a leading cause of nosocomial diarrhoea and antibiotic-associated gastrointestinal infection. C. difficile infection (CDI) is emerging as a serious threat worldwide. 1, 2 The incidence of CDI among residents of long-term tertiary care facilities and in the community has increased in recent years. 3 -6 Pathogenic strains of C. difficile produce exotoxins called toxin A and toxin B, which cause mucosal damage and inflammation of the colon. A recently identified C. difficile strain (NAP1/027/BI, North American PFGE type 1) has caused severe outbreaks in North America and Europe, producing cytotoxin for a longer duration than other endemic strains. 7 -9 Transmission of C. difficile within hospitals and nursing homes occurs due to the production of long-lasting, heat-resistant spores, which may persist for many years. 10 Moreover, C. difficile is a unique pathogen, because antibiotic exposure is virtually a prerequisite for infection and most common antibiotics, i.e. fluoroquinolones, clindamycin, ampicillin, amoxicillin and cephalosporins, have been linked to the induction of CDI. 11 At present, the antibiotics of choice for the treatment of CDI are metronidazole for mild to moderate cases and vancomycin (the only agent approved by the FDA) for moderate to severe cases. Oral metronidazole is preferred in most cases, because of its low cost, while oral vancomycin is considered a second-line of treatment, because of the potential for the selection of vancomycin-resistant Enterococcus and its high cost. 1 However, in recent reports, metronidazole showed reduced efficacy against CDI caused by hypervirulent strains. 12, 13 Furthermore, Zar et al. 12 demonstrated that metronidazole and vancomycin are equally effective in mild cases, whereas vancomycin is more efficacious in severe cases. Metronidazole treatment may also result in significant side effects, including neuropathy, seizures and abdominal pain. 6, 12, 14 Several approaches, such as probiotic therapy, toxin-binding polymers, monoclonal antibodies against C. difficile toxins and new anti-C. difficile drugs, have been assessed in the management of CDI; however, their clinical efficacy is still under evaluation. 15 -23 Therefore, there is an unmet medical need for a better treatment for CDI.
Linezolid is an oxazolidinone that exhibits antibacterial activity by inhibiting bacterial protein synthesis and is active against several Gram-positive pathogens, including anaerobes. In vitro activity of linezolid against C. difficile has been described in only a few reports. 24 -26 Ranbaxy Research Laboratories, Gurgaon, India, has synthesized a series of novel biaryl oxazolidinone compounds as part of an antibacterial drug discovery programme and many of these compounds demonstrated potent activity against various Gram-positive bacteria. 27 Looking at the complexity of CDI as well as the urgent need for an effective antibacterial agent, we have identified RBx 11760, a potent novel biaryl oxazolidinone compound (Figure 1 ), and profiled it against C. difficile, with special reference to its activity against clinical isolates, spores and toxin production.
Materials and methods

Bacterial strains
The strains used for in vitro susceptibility studies were C. difficile ATCC 43255 (VPI 10463), ATCC 43596 and ATCC 9689 from the American Type Culture Collection (ATCC, Rockville, MD, USA), and NAP1/027/BI-type strains 2009155 and 2004118 from the Centers for Disease Control and Prevention (Atlanta, GA, USA). C. difficile NCTC 11223 was purchased from the National Collection of Type Cultures, London, UK. Forty-five clinical isolates of C. difficile and 10 isolates of other Clostridium spp. were obtained from a tertiary care medical centre (PGIMER, Chandigarh) in India.
C. difficile isolates 6387 PGI 1 and C. difficile 6429 obtained from clinical sources were used for time-kill experiments, sporulation assays and resistance development studies. Other bacterial strains used in this study (Peptostreptococcus spp., Propionibacterium acnes, Bacteroides spp. and Prevotella spp.) were obtained from the ATCC and tertiary care medical centres (AIIMS, New Delhi; Sufdarjung Hospital, New Delhi; and ONGC Hospital, Dehradun, India). Reference anaerobe strains Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 were also included when performing antibiotic susceptibility assays. C. difficile strains were maintained on Wilkins-Chalgren agar (WCA; Oxoid, USA) and cycloserine-cefoxitin-fructose agar (CCFA; Hi Media, India) under anaerobic conditions (80% nitrogen, 10% carbon dioxide and 10% hydrogen). The identity of the clinical isolates used in this study was confirmed by their colony morphology, Gram staining, glutamate dehydrogenase immunoassay (Tech Lab, T-5025) and biochemical tests.
Antimicrobial agents
RBx 11760 was synthesized in the Department of Medicinal Chemistry, Ranbaxy Research Laboratories, Gurgaon, India. Vancomycin was obtained from the API manufacturing facility of Ranbaxy Laboratories, Gurgaon, India. Metronidazole was purchased from Sigma-Aldrich (St Louis, MO, USA). Linezolid was synthesized at the National Chemical Laboratory, Pune, India. Stock solutions of RBx 11760 and metronidazole were prepared in DMSO, while vancomycin and linezolid were dissolved in sterile distilled water at a concentration of 1 mg/mL.
Antibiotic susceptibility studies
The MICs of RBx 11760, vancomycin, metronidazole and linezolid were determined by the agar dilution method, according to CLSI guidelines. 28 Briefly, serial 2-fold dilutions of the tested drugs were prepared and added to Brucella agar (BA; Difco, USA) supplemented with vitamin K1 (0.5 mg/L), haemin (5 mg/L) and 5% laked sheep blood to prepare the plates. Inocula were prepared according to the CLSI method and spotted on the plates with a replicator (Denley, UK) to obtain a final inoculum of 10 5 cfu/spot. Plates were placed in a jar under anaerobic conditions adjusted with an Anoxomat (Mart, Germany) and incubated at 378C for 48 h. The plates were examined after 48 h and the MICs were determined. In vitro results were analysed using WHONET software version 5.3.
Killing kinetics
The time-kill kinetics of RBx 11760, vancomycin, metronidazole and linezolid were determined against C. difficile ATCC 43255 and C. difficile 6387 (clinical isolate), according to the method described by Yagi and Zurenko. 29 Anaerobic broth medium (Difco Laboratories, USA) supplemented with 5% lysed horse blood was pre-warmed at 378C in reaction tubes and the drug was added at multiple concentrations ranging from 1× to 16× MIC. The bacterial cultures grown to log phase were adjusted to 1.0 McFarland standard (Densimat; bioMérieux, SA, France), further diluted and added to the reaction tubes to give a final inoculum of 1×10 6 cfu/mL. The experiment was performed in an anaerobic chamber (Bactron IV; Sheldon Mfg, Cornelius, OR, USA) and the tubes were incubated at 378C under anaerobic conditions. Sampling was performed at 0, 4, 8, 24 and 30 h, and serial doubling dilutions of suspensions were plated on CCFA plates. Plates were incubated at 378C for 48 h in anaerobic conditions. Plates yielding 30-300 colonies were selected to determine cfu/mL values. Each experiment was performed three times to confirm the results. The rate and extent of the killing were determined by plotting mean viable counts (log 10 cfu/mL) against time (h). The bactericidal potential of the antibiotic was considered as the lowest concentration that reduced the initial inoculum by ≥3 log 10 cfu/mL (99.9%) over each time period; the antibiotics were considered bacteriostatic if the inoculum was reduced by 0 to ,3 log 10 cfu/mL.
Effect of RBx 11760 on C. difficile sporulation
The sporulation assay was carried out as described by Ochsner et al. 30 RBx 11760, vancomycin, metronidazole and linezolid were tested for their inhibition of sporulation using the high spore-producing C. difficile strain ATCC 43596 and a clinical isolate (PGI 1). The cultures grown overnight were diluted in pre-reduced PBS (pH 7.2) to obtain 1×10 5 cfu/mL, Mathur et al.
and 0.1 mL was spread on BA plates containing different concentration of drugs (0.06-2× MIC) and a drug-free control. After 6 days of anaerobic incubation, viable growth was removed from all plates and suspended in 1 mL PBS. Half of this suspension was used to prepare spores by killing vegetative cells through the addition of an equal volume of ethanol with intermittent vortexing for 1 h. Serial 10-fold dilutions of these suspensions were plated on WCA plates and incubated for 48 h at 378C, under anaerobic conditions, and viable cell counts and spore counts were obtained separately. Sporulation was also confirmed with the Wirtz -Conklin staining method (5% malachite green/0.5% safranin). 31 Each experiment was repeated three times, and the viable cell count (cfu/mL) and spore count were used to calculate the mean percentage of spores and standard deviation on drug-treated and control plates.
Effect of sub-MIC concentration on toxin production C. difficile ATCC 43255 (toxinotype 0) and C. difficile 6429 (clinical isolate) were used for the toxin production study. The effect of sub-MIC concentrations of drugs on C. difficile toxin production was measured as described by Gerber et al. 32 In brief, C. difficile strains were inoculated into pre-reduced brain heart infusion (BHI, Difco) broth for overnight incubation. Cultures were centrifuged, washed and diluted 10-fold with fresh BHI broth to a concentration of 10 6 -10 7 cfu/mL, and 10 mL was then dispensed in test tubes. Different concentrations (0.25× and 0.5× MIC) of each drug were added to the tubes before incubating at 378C in an anaerobic chamber. Samples (0.5 mL) were withdrawn at 0, 4, 8, 12, 24, 48 and 96 h time intervals. Part (0.1 mL) of this suspension was used for determining the viable cell count; the remainder was centrifuged (10 min, 4000 rpm) and the supernatant was subsequently filtered (0.2 mM, Millipore). Serial 10-fold dilutions (10 1 - 10 7 ) of supernatant were prepared in RPMI 1640 medium (Roswell Park Memorial Institute medium, Hyclone, USA) with 1% fetal calf serum and used for determining toxin A/B titres.
Toxin A/B titres were measured by in a tissue culture system using the Vero cell line. Cells were maintained in tissue culture flasks (Nunc, Roskilde, Denmark) in RPMI 1640 medium supplemented with 10% fetal bovine serum and kept at 378C in an atmosphere of 5% CO 2 . Seeding was performed in 96-well tissue culture plates (Nunc) at cell densities of 1×10 5 cells/mL in fresh RPMI medium to achieve a monolayer. The Vero cell monolayer was washed with PBS to remove traces of culture medium and 0.1 mL of the supernatant dilutions was added. After 18 -24 h of incubation, the cytopathic effect (CPE, rounded cells) was determined by microscopy, 30 and the highest dilution resulting in ≥50% cell rounding was considered as a positive CPE and toxin titre. The ELISA method was used to detect toxin A/B (TechLab Inc., Blacksburg, VA, USA) simultaneously in the supernatant in 96-well microtitre plates, as per the manufacturer's instructions.
Frequency of resistance
The emergence of spontaneous resistance in the presence of the antibiotic was determined by using C. difficile ATCC 43255 and C. difficile 6387 at three inoculum levels. BA plates with laked sheep blood containing two concentrations (4× and 8× MIC) of RBx 11760, vancomycin, metronidazole and linezolid were prepared. A 0.1 mL aliquot of high cell density culture ( 5.0×10 9 cfu/mL) was spread on the plates and incubated for 48 h at 378C under anaerobic conditions. The viable count of the inoculum was determined by the spiral plater spread method (Spiral Biotech, Bethesda, MD, USA). The frequency of resistance was calculated by dividing the average number of colonies obtained on drug-containing plates by the total viable count.
In vitro development of resistance
For determining the ability of C. difficile ATCC 43255 and C. difficile 6429 to develop resistance against RBx 11760 and other standard drugs, a serial passage method was used. Serial 2-fold dilutions of RBx 11760 and other drugs were prepared in tubes with pre-reduced BHI broth (1 mL), and 100 mL of diluted culture (10 5 -10 6 cfu/mL) was added. After incubation at 378C for 48 h under anaerobic conditions, initial inhibitory concentrations were recorded and growth from sub-MIC levels was used for subsequent passage. After 25 passages, the stability of resistant mutants was determined by subculturing on drug-free BA with 5% sheep blood (5 passages), followed by determination of MICs. Confirmation of acquired resistance was performed by subculturing on antimicrobialcontaining plates (428× MIC).
In vivo efficacy
Experimental animals
Golden Syrian hamsters weighing 80-100 g were purchased from the National Institute of Nutrition, Hyderabad, India. Hamsters were housed in plastic cages in an air-conditioned pathogen-free animal room and allowed 1 week of acclimatization before initiation of the experiment. All animal studies were conducted as per the guidelines of the Institutional Animal Ethics Committee, Ranbaxy Research Laboratories, Gurgaon, India and the Committee for the Purpose of Control & Supervision of Experiments on Animals, New Delhi. Feed and water were provided ad libitum during the whole study. Six hamsters were taken per treated group as well as per untreated control group.
Hamster model of C. difficile gastrointestinal infection
Hamsters were given a single subcutaneous injection of clindamycin phosphate (30 mg/kg formulated in phosphate buffer, pH 7.2) on day 21, to render them susceptible to C. difficile infection. On day 0, hamsters were infected by oral gavage with 1 mL of C. difficile ATCC 43596 suspensions (5×10 7 cfu/mL) prepared from cultures grown overnight on WCA at 378C. Treatment was started at the beginning of day 1 with either vehicle, RBx 11760 (50 mg/kg), vancomycin (5 mg/kg) or metronidazole (150 mg/kg), given twice a day for 5 consecutive days. 30, 33 Oral doses of RBx 11760 and metronidazole were formulated in 0.25% methyl cellulose, and those of vancomycin were formulated in sterile Milli-Q water. An infected control and an uninfected control were also included in this study. Hamsters were monitored twice daily for morbidity and mortality, and the presence or absence of diarrhoea for 5 days and daily thereafter.
Histopathology studies
A satellite group of untreated hamsters (n¼3) was kept for the histopathology study along with each respective treatment group. Samples for histopathological examination were collected from the untreated animals 3 days after the start of the experiment, and from the test animals 3 days after discontinuing treatment with RBx 11760, vancomycin and metronidazole. For histopathology, the whole caecum was collected and preserved in 10% neutral buffered formalin. Samples were coded before being submitted to the pathology laboratory. Paraffin-embedded tissue sections were cut at 3 -4 mm thickness, stained with haematoxylin and eosin by using an Autostainer XL, and mounted using DPX mount for microscopic examination. The slide reading was performed using a blinding code. The inflammatory changes in the hamster caeca were scored based on the overall lesion-occupying percentage of the tissue section. The score was 1 for minimal (,10%), 2 for mild (.10% but ,25%), 3 for moderate (.25% but ,40%), 4 for severe (.40% but ,60%) and 5 for very severe (.60%). Macromolecular synthesis inhibition studies were performed as described previously, 34 with some modifications. Briefly, C. difficile ATCC 43255 was grown to early log phase [optical density at 600 nm (OD 600 ) of 0.3] in BHI broth media under anaerobic conditions. 14 C-labelled isoleucine and acetic acid (both 2.0 mCi/mL), and 1.0 mCi/mL 3 H-labelled thymidine, uridine and N-acetylglucosamine from (GE Healthcare, Amersham, Bucks, UK) were used as precursors for protein, lipid, DNA, RNA and cell wall synthesis, respectively. Radioactive precursors were added during the early logarithmic phase and 3 min before the addition of RBx 11760, vancomycin, metronidazole and linezolid at the sub-MIC level. At 2 and 6 h time intervals, ice-cold trichloroacetic acid (TCA) (10% w/v) was added to the wells to achieve a 5% w/v final concentration. The TCA-precipitable material was filtered on A/B glass fibre 96-well filter plates (Pall Corporation, MI, USA) and washed twice with 5% w/v TCA (150 mL) using a Millipore 96 FilterMate Harvester. Plates were dried overnight at room temperature. Plates were read in a MicroBeta JET liquid scintillation counter (Perkin Elmer, Waltham, MA, USA) after addition of the liquid cocktail.
The effect of RBx 11760 and linezolid on protein synthesis was observed by pulse labelling of cells with 14 C-labelled isoleucine in the presence of various drug concentrations (0.03-32 mg/L) against C. difficile ATCC 43255. Samples were evaluated after 6 h of incubation and radioactivity was detected as described above.
Statistical analysis
Comparison of results between the groups was performed by one-way analysis of variance and multiple comparisons used Dunnet's multiple comparison post-test. A P value of ,0.01 was considered statistically significant. The statistical analysis was performed using GraphPad Prism-4 (GraphPad Software, San Diego, CA, USA).
Results and discussion
CDI mainly occurs in hospitals or long-term care facilities. Over the last few years, its incidence has increased dramatically and it is now considered a major clinical problem around the globe. 10 The in vitro activity of RBx 11760, vancomycin, metronidazole and linezolid against C. difficile isolates is summarized in Table 1 . RBx 11760 was highly active against the C. difficile isolates (MIC 50/90 0.5 and 1 mg/L; range 0.25 -1 mg/L). RBx 11760 also exhibited activity against other anaerobes (Clostridium spp. and anaerobic Gram-positive cocci; Table 1 ). Vancomycin and metronidazole were found to be equally potent against C. difficile (MIC 50/90 ) 1 -4 mg/L and 0.5 -1 mg/L, respectively. Similarly, linezolid showed an MIC 50/90 of 4 and 8 mg/L, although elevated MICs were observed in two C. difficile isolates (MIC 16 mg/L). RBx 11760 was active against aerobic Gram-positive cocci, such as Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium (MIC 90 ,1 mg/L), but not active against most Gram-negative bacteria (data not shown).
Clinical isolates of C. difficile with high vancomycin and metronidazole MICs (8 mg/L) were susceptible to RBx 11760 (0.5-1 mg/L), although the number of resistant isolates available for evaluation was limited in our collection (Table 1) . RBx 11760 was also active against two C. difficile hypervirulent NAP1/027/BI strains (MICs 0.5 and 2 mg/L), whereas vancomycin, metronidazole and linezolid exhibited similar activities, with MICs ranging from 1 to 2, 0.5 to 1 and 2 to 4 mg/L, respectively, for these C. difficile strains.
RBx 11760 showed a high MIC 90 (16 mg/L) for Gram-negative anaerobes, i.e. Bacteroides spp., whereas the MIC 90 values of metronidazole and linezolid were 2 and 8 mg/L, respectively. To better understand the impact of RBx 11760 in maintaining the equilibrium of normal gastrointestinal flora, a larger panel of intestinal flora would need to be screened in conjunction with pharmacokinetic/pharmacodynamic (PK/PD) studies in humans. 35 For the reference strains B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741, the MICs of vancomycin, metronidazole and linezolid were within the acceptable ranges described by the CLSI. 28 In order to assess the killing potential of RBx 11760, we performed time-kill kinetic studies against C. difficile ATCC 43255 and clinical isolate C. difficile 6387. Against both isolates, MICs of RBx 11760, vancomycin, metronidazole and linezolid were 0.5, 0.25, 1 and 2-4 mg/L, respectively. The average results obtained from three independent time-kill-kinetic experiments with varied drug concentration and different timepoints are presented in Figure 2 . The data demonstrated that RBx 11760 exhibited concentration-dependent bactericidal activity (≥3.0 log 10 cfu/mL reduction) against both C. difficile ATCC 43255 and C. difficile 6387. RBx 11760 showed a bactericidal effect against C. difficile ATCC 43255 at 2 mg/L (4× MIC), even at 8 h, whereas against C. difficile 6387 a .3.0 log 10 cfu/mL reduction was achieved at 4 mg/L at 24 h. Metronidazole showed bactericidal activity at 0.5 mg/L (2× MIC) against C. difficile ATCC 43255 and C. difficile 6387 at 8 and 24 h, respectively. However, vancomycin showed bactericidal activity against both isolates only after 24 h of exposure at 2 mg/L (2× MIC) concentration. Linezolid at the higher concentration of 16 mg/L (8× MIC) exhibited a 3.0 log 10 cfu/mL reduction against C. difficile ATCC 43255, whereas at the same concentration against C. difficile 6387 (4× MIC) only a 2 log 10 cfu/mL reduction was observed after 24 h of exposure (Figure 2 ). Our observations of linezolid being bactericidal against anaerobes are in agreement with an earlier report. 29 C. difficile strains ATCC 43596 and PGI 1 were used for assessing the rate of sporulation. They were susceptible to RBx 11760 (0.5 and 1 mg/L), vancomycin (1 and 2 mg/L) and metronidazole (0.25 and 1 mg/L), but linezolid MICs were slightly elevated (16 and 4 mg/L for C. difficile ATCC 43596 and C. difficile PGI 1, respectively). After 6 days, C. difficile ATCC 43596 and C. difficile PGI 1 showed mean viable counts of 4.0×10 6 and 2.6×10 6 cfu/mL in drug-free control medium, and the spore count appeared to be 4.0×10 5 (10%) and 2.0×10 5 cfu/mL (7.6%), respectively. These spores (spheres) were differentiated from rod-shaped vegetative cells by Wirtz -Conklin staining.
Treatment with RBx 11760 at 0.5× and 0.25× MIC caused a significant reduction (P,0.01) of sporulation compared with vancomycin and metronidazole, and the cells appeared to remain in the vegetative state. Against C. difficile PGI 1 and C. difficile ATCC 43596, spore formation was inhibited in a dose-dependent manner and no sporulation was observed at 0.5× MIC, whereas at 0.25× and 0.125× MIC, 5%-10% and 20% -25% spores were observed, respectively (Table 2) . Treatment with vancomycin and metronidazole did not reduce sporulation; in fact, spore counts were almost similar to viable vegetative cell counts (100% Activity of RBx 11760 against C. difficile sporulation) in the presence of 0.125 -0.5×MIC against both of the isolates. This observation is in agreement with a previous study where vancomycin and metronidazole appeared to promote the formation of spores, which may be a cause of relapse after treatment. 30 Linezolid at 0.25× MIC also reduced spore formation by C. difficile PGI 1 and C. difficile ATCC 43596 by 70% and 52%, respectively. Thus, RBx 11760 showed an advantage over vancomycin, metronidazole and linezolid in controlling C. difficile spore formation (Table 2) .
C. difficile strains ATCC 43255 and 6429 produced measurable levels of toxins A/B after 8 and 12 h of incubation, respectively. The level of toxin production was different, with C. difficile ATCC 43255 producing more toxin (titre: 5 log 10 CPE units/mL) than C. difficile 6429 (titre: 4 log 10 CPE units/mL) after 24 h. In the presence of sub-MIC concentrations (0.25× and 0.5×), the growth of both isolates was almost the same as that seen in drug-free control medium. Representative graphs for C. difficile ATCC 43255 in the presence of 0.5× MIC of drugs are shown in Figure 3 . As evident by cytotoxicity assays and ELISA, vancomycin, metronidazole and linezolid did not reduce the level of toxin A/B production at 0.25× and 0.5× MIC when compared with cultures grown in drug-free control medium, even though the drug exposure was for a prolonged period (Figure 3 ). In contrast, toxin A/B levels were reduced by 100-to 1000-fold after 18-24 h of RBx 11760 exposure at both concentrations (0.25× and 0.5× MIC, respectively; Figure 3b and 3c). Our observations for vancomycin, metronidazole and linezolid are in agreement with earlier reports about increased toxin A/B levels in C. difficile after drug exposure (Figure 3 ). 32 The frequencies of spontaneous mutations for resistance to RBx 11760 observed in C. difficile ATCC 43255 were 1.5×10 29 and ,6.5×10 29 , whereas in C. difficile 6387 the frequencies were 2.0×10 29 and 3.0×10 29 at 4× and 16× MIC, respectively. The frequencies of resistance to vancomycin, metronidazole and linezolid were comparable to those for resistance to RBx 11760 in both the C. difficile isolates, while the positive control rifampicin showed a higher possibility for resistance development (Table 3) . C. difficile ATCC 43255 and 6429 isolates remained susceptible to RBx 11760, even after 25 passages, and only a 2-fold shift in MICs was observed. Similarly, when passaging was done in the presence of metronidazole and linezolid, C. difficile isolates did not develop any kind of resistance to these drugs and MICs shifted only 2 -4-fold. Therefore, C. difficile appeared to have little propensity to develop resistance to RBx 11760, metronidazole and linezolid. However, against vancomycin, moderate levels of resistance were observed during passaging and phenotypes obtained from both isolates were stable and showed increased MICs (4 -8-fold) ( Table 4 ).
In vivo efficacy of RBx 11760 in a hamster model of C. difficile
The activity of RBx 11760 was assessed in the widely used hamster model of CDI. 36, 37 The survival of animals treated with RBx 11760, metronidazole and vancomycin as compared with the untreated control is depicted in Figure 4 . By day 5, the entire untreated group had died of diarrhoea, while animals treated with metronidazole began to develop disease after cessation of treatment and died within 3 -8 days. In contrast, RBx 11760 at a dose 50 mg/kg reduced the incidence of diarrhoea and led to a higher survival rate than that seen among hamsters treated with the comparator antibiotics. The administration of RBx 11760 resulted in the survival of 100% of treated animals as compared with 50% and 0% of those receiving vancomycin and metronidazole, respectively, by day 13. Treatment with RBx 11760 resulted in 100% survival until 8 days after treatment. While no mortality occurred in the vancomycin-treated group during 7 days of treatment, all subsequently succumbed to diarrhoea and died within 3 days. In the RBx 11760-treated group, 50% of the animals survived until 14 days post-treatment, compared with 0% survival in the metronidazole-and vancomycintreated groups.
Grossly, the colons and caeca of infected control animals appeared enlarged, and were filled with fluid and foul-smelling faeces. Histological examination of the caeca of untreated infected animal revealed a marked inflammatory infiltration, oedema and necrosis of the villi ( Figure 5 ). However, caeca Activity of RBx 11760 against C. difficile from RBx 11760-treated animals showed a mild inflammatory response with minimal infiltration of neutrophils and epithelial damage. Vancomycin-and metronidazole-treated animals showed moderate inflammatory infiltration and epithelial damage, and reduced congestion as well as oedema as compared with untreated controls. Overall, the histological changes observed in caeca of animals treated with various drugs indicated their potential to eliminate the bacterial infection and inflammatory changes. The inhibitory effect of RBx 11760 on the incorporation of radiolabelled precursors for macromolecule (RNA, DNA, protein, cell wall and lipid) synthesis was determined ( Figure 6 ). RBx 11760 resulted in 55% inhibition of isoleucine incorporation in protein at 2 h of compound addition, which increased to 70% inhibition after 6 h of incubation. No inhibition of DNA, RNA and cell wall synthesis was observed for RBx 11760 and linezolid. However, linezolid showed 43% inhibition of lipid synthesis ( Figure 6 ).
Protein synthesis inhibition by RBx 11760 and linezolid is presented in Figure 7 . RBx 11760 showed 40% -50% inhibition of [ 14 C]isoleucine incorporation at sub-MIC concentrations, whereas linezolid showed inhibition only at concentrations equal to or above the MIC (Figure 7) . The mode of action of RBx 11760 through inhibition of protein synthesis could be a possible explanation as to why it effectively blocks clostridial toxin production as well as possibly interfering with the synthesis of the protein coat, which has the effect of lowering the rate of sporulation. Since standard treatment regimens for CDI are vancomycin, which inhibits the late stage of cell wall synthesis in growing cells, and metronidazole, which causes non-specific radical-mediated DNA damage, it has been suggested that these agents are unable to prevent toxin and spore formation. 30 RBx 11760 is a potent and selective protein synthesis inhibitor, even at sub-MIC levels. This mechanism of action could be the reason for its potential in vitro activity against resistant C. difficile and in attenuating toxin production as well as preventing sporulation, which indicates that it may have an advantage in the hospital setting, where spores are the main source of new infections and recurrence. However, extensive susceptibility profiling of RBx 11760 against diverse C. difficile strains from different regions together with PK/PD studies as well as animal safety studies are required before RBx 11760 can be advanced for clinical testing. 
